Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
about
Calcineurin determines toxic versus beneficial responses to α-synuclein.Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agentsImpact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseaseEffects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's diseases in Balb/c miceThe etiopathogenesis of Parkinson disease and suggestions for future research. Part II.Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.Population-based prospective study of cigarette smoking and risk of incident essential tremor.Environmental epidemiology of essential tremor.The impact of subthalamic deep brain stimulation on nigral neuroprotection-myth or reality?Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice.Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease.Limitations of animal models of Parkinson's disease.Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway.Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway.FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome.Nifedipine prevents iron accumulation and reverses iron-overload-induced dopamine neuron degeneration in the substantia nigra of rats.Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.
P2860
Q34120215-FA545971-62C3-437B-AE31-D770F2C729B3Q35045060-E85A3995-9823-4A4E-8047-31D2F2E4CAC7Q35546008-98F0FDCF-E1F1-4D5A-A059-2A7366D0088EQ36462680-8B69718A-4F72-4ED3-9A9A-2FC743909E98Q36582947-55D3F87F-1719-4CA8-96C4-C74B13A94BF0Q36812817-01B1F38B-927F-4E86-AD96-B132F6B21480Q36919155-5CE700F9-2205-4E4F-A90F-DD2D4917E1DCQ37076726-13BA3230-FA19-4FCE-A41F-240B70099CB8Q37195940-C3969A8A-BCE7-4D3C-9AAF-B197D52B1AC0Q37196824-93F19843-D491-4180-B9C4-E63025773F52Q37944953-2D608A11-35EA-4768-8322-AF6D9C67EDB0Q37946305-7286BBDD-1D4A-4B6F-B987-92954F45DD30Q39124093-463C1A3B-0CDD-4788-9D7E-738C73181204Q39959282-F055DFB9-3805-4164-B72C-9F57C456E129Q41108404-81006BA8-ADFE-4236-8CCA-B7CB57D710EEQ41349377-F112797A-21B7-41A3-95AB-5668A972FD73Q41442155-0053B333-4C87-4AED-9298-7A6A34CCDF8FQ41488512-E1108636-CD58-4F4C-8E47-66E6E896CC03Q44266420-D342CFF1-0D95-4964-A571-7C90E5463701Q46677370-D46B6F4F-DF7E-4C1B-9516-F6E4969A04B7Q46881742-2A4A3D8C-494C-497E-B2C7-C5C8CEDEA840Q47304900-49320903-C75E-429B-8733-9280A88B2133Q48703945-AF1C5244-6B02-47D6-AB87-FABC2E753D2BQ51020610-D5A7DD39-96CE-49E5-89FD-3B5193018F29
P2860
Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Neuroprotective strategies for ...... al models and clinical trials.
@ast
Neuroprotective strategies for ...... al models and clinical trials.
@en
type
label
Neuroprotective strategies for ...... al models and clinical trials.
@ast
Neuroprotective strategies for ...... al models and clinical trials.
@en
prefLabel
Neuroprotective strategies for ...... al models and clinical trials.
@ast
Neuroprotective strategies for ...... al models and clinical trials.
@en
P2093
P1476
Neuroprotective strategies for ...... mal models and clinical trials
@en
P2093
Christian E Gross
François Tison
Michael P Hill
P304
P356
10.1016/J.TIPS.2004.03.003
P577
2004-05-01T00:00:00Z